Discovery platform
De-risk your pipeline by discarding unsafe molecules early on, with QT prolongation predictions.
How Discovery works
1
Input heart ion channel measurements
of your candidates
2
Predict human QT prolongation
and arrhythmic cases
3
Compare, identify and
discard unsafe candidates
Key benefits
Exploit the benefits of cardiac safety predictions.
Use QT Prolongation predictions to anticipate the risk of your compounds at an early stage and decide which candidates are worth further exploration.
Characterise compounds using ion channel IC50 - H measurements or through probability distributions and explore all possible combinations.
Account for environmental shifts by toggling between saline buffer and plasma measurements.
Get cardiac safety prediction for the whole concentration space around your target concentration and different protein bindings.
Study edge cases such as accidental or intentional drug abuse.
Understand the risk profile of your compounds through a sex-specific analysis of the QT prolongation and arrhythmia predictions for all channel measurement combinations, accounting for sex-based variability.
Take it from Discovery to Development
Avoid changing the study model between pipeline stages.
Simulate your promising compounds with V.HEART Trials to get granular around different virtual patient populations.
Discard unsafe molecules
Simulate your promising compounds
Take full control over the population of interest
What we offer
Leverage cardiac safety prediction and discard unsafe molecules early on
First arrhythmic cases
Combinations that produce min/max ΔQT
QT response analysis by sex
Concentration range for ΔQT of 10ms
How does our technology work?
ELEM’s technology combines patient-specific data, high-performance physics-based simulation, and advanced computational modeling to create Virtual Human Twins.
Integrating in your pipeline cardiac safety prediction, opens the door to faster, safer, and data-driven early clinical decisions.
Get started with ELEM Cardiac Safety Prediction Platform
One of our experts will get in touch with you
